[1] COWAN A J, ALLEN C, BARAC A, et al. Global burden of multiple myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016[J]. Jama Oncol, 2018, 4(9): 1221-1227.
[2] RÖLLIG C, KNOP S, BORNHÄUSER M. Multiple myeloma[J]. Lancet, 2015, 385(9983): 2197-2208.
[3] WU C, ZHANG L, BROCKMAN Q R, et al. Chimeric antigen receptor T cell therapies for multiple myeloma[J]. J Hematol Oncol, 2019, 12(1): 120.
[4] ZHAO W N H, LIU J, WANG B Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2018, 11(1): 141.
[5] LIN Q, ZHAO J, SONG Y,et al. Recent updates on CAR T clinical trials for multiple myeloma[J]. Mol Cancer,2019,18(1):154.
[6] ZANWAR S, ABEYKOON J P, KAPOOR P. Challenges and strategies in the management of multiple myeloma in the elderly population[J]. Curr Hematol Malig Rep, 2019,14(2): 70-82.
[7] PALUMBO A, BRINGHEN S, MATEOS M V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report[J]. Blood, 2015, 125(13): 2068-2074.
[8] KUMAR S, PAIVA B, ANDERSON K C, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016, 17(8): e328-e346.
[9] NEELAPU S S, TUMMALA S, KEBRIAEI P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018,15(1):47-62.
[10] TAI Y T, ANDERSON K C. Targeting B-cell maturation antigen in multiple myeloma[J]. Immunotherapy, 2015, 7(11): 1187-1199.
[11] BRUDNO J N, MARIC I, HARTMAN S D, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J]. J Clin Oncol, 2018, 36(22): 2267-2280.
[12] JIANG S, JIN J, HAO S, et al. Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed/refractory multiple myeloma[J]. Blood, 2018, 132(Suppl 1): 960. |
